Drew Moghanaki, Professor, Chief of Thoracic Oncology at the Department of Radiation Oncology and Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at David Geffen School of Medicine at UCLA, and Chief Medical Officer of Respirati, shared a post on LinkedIn about a recent article by Patrick Goodley et al, published in Journal of Thoracic Oncology:
“Be wary of anti-screening voices like Gilbert Welch and Vinay Prasad, whose rhetoric often relies on gaslighting and distortion rather than evidence.
The facts remain clear: lung cancer screening saves lives.
Annual low-dose CT screening reduces stage IV diagnoses by detecting cancer earlier, when a cure is still possible. Now, the Manchester group has reinforced that reality once again, analyzing a regional population of more than 1.2 million people and demonstrating a 22% reduction in late-stage lung cancer incidence among those screened.
The evidence continues to accumulate.
Lives continue to be saved.
The science is not ambiguous.”
Title: Population Impact of Risk-Based Lung Cancer Screening on Late-Stage Incidence in Greater Manchester
Authors: Patrick Goodley, Haval Balata, Alberto Alonso, Anna Sharman, Louise Brown, Rehan Naseer, Haider Al-Najjar, Zoe Merchant, Kath Hewitt, Coral Higgins, Richard Booton, Hilary Robbins, Matthew Sperrin, Philip Crosbie
Read the Full Article on Journal of Thoracic Oncology.
More posts featuring Drew Moghanaki.
